Revelation Biosciences, Inc. (REVB) AI Stock Analysis

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company dedicated to advancing immune system therapeutics and diagnostics. Headquartered in San Diego, California, the company develops treatments for critical medical conditions. Its pipeline includes REVTx-100 for healthcare-associated bacterial infections from surgical procedures, burns, and antibiotic resistance. It is also developing REVTx-200, an intranasal therapy, and REVTx-300 for chronic organ diseases like chronic kidney disease and non-alcoholic steatohepatitis. Additional programs include REVTx-99b for food allergies, REVTx-99a for respiratory viral infections, and REVDx-501, a rapid point-of-care diagnostic kit for viral infections like SARS-CoV-2 and influenza strains.

Between FY2015 and FY2019, annual revenue increased from $27.7M to $95.8M, representing a 4-year revenue compound annual growth rate of 36.4%. Net income was $6.2M in FY2015, rising to $27.6M in FY2018 before dropping to -$3,638 in FY2019 alongside an operating margin of -0.0%. For the trailing twelve months ended June 30, 2026, revenue stood at $0, with both operating margin and profit margin at 0.0%. Diluted earnings per share for the trailing twelve months were $4.60, while return on equity was -154.8% and return on assets was -78.7%.

As of June 30, 2026, Revelation Biosciences held $11.5M in cash and short-term investments and $739,916 in total debt, resulting in net cash of $10.7M. Total assets were $12.5M against shareholders' equity of $10.1M. The company reported a current ratio of 6.21 and a debt-to-equity ratio of 0.07. In FY2025, the company recorded dividends paid of $5.95B, while its share count expanded by 935.5% over a 5-year period.

At a share price of $0.48 on October 16, 2026, Revelation Biosciences had a market capitalization of $1.9M and an enterprise value of -$6.8M. The stock trades at a trailing price-to-earnings ratio of 0.1x and a forward price-to-earnings ratio of 0.9x, compared to medians of 24.6x and 17.3x, respectively, for US-listed Healthcare peers. Its price-to-sales ratio is 2.9x compared to the peer median of 4.1x, and its price-to-book ratio is 0.4x. Over the past year, the stock fell 90.9%, while the S&P 500 returned 16.8%.

Wall Street coverage includes 1 Strong Buy rating, 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The mean price target is $17.75, representing a 3559.8% premium over the last close of $0.48. For the fiscal year ending December 31, 2026, the consensus estimates an EPS of -$5.18 on $0 in revenue. For the following fiscal year, 2 analysts project an EPS of -$2.89 on $0 in revenue. The company recorded 0 EPS beats over the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Revelation Biosciences, Inc. (REVB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: REVB income statement, REVB balance sheet, REVB key metrics, REVB analyst forecast, REVB chart. See the REVB stock overview for the latest quote and news.